Table 1.
Susceptibility results of the main Candida species strains of the AmarCAND2 study to the triazoles and echinocandins according to specimen source.
| Species∗ | Categorization [N (%)] | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specimen source (No. of strains) | Fluconazole | Voriconazole | Anidulafungin | Micafungin | Caspofungin | ||||||||||
| S or WT | I | R or non-WT | S or WT | I | R or non-WT | S or WT | I | R or non-WT | S or WT | I | R or non-WT | S or WT | I | R or non-WT | |
| C. albicans | |||||||||||||||
| Blood | 96 (93) | 4 (4) | 3 (3) | 100 (97) | 3 (3) | 0 | 101 (98) | 2 (2) | 0 | 100 (97) | 2 (2) | 1 (1) | 101 (98) | 2 (2) | 0 |
| Peritoneal | 124 (93) | 4 (3) | 5 (4) | 128 (96) | 5 (4) | 0 | 133 (100) | 0 | 0 | 133 (100) | 0 | 0 | 132 (99) | 1 (1) | 0 |
| Other | 47 (96) | 0 | 2 (4) | 49 (100) | 48 (98) | 1 (2) | 48 (98) | 1 (2) | 48 (98) | 1 (2) | |||||
| All (285) | 267 (94) | 8 (3) | 10 (4) | 277 (97) | 8 (3) | 0 | 282 (99) | 2 (0.7) | 1 (0.3) | 281 (99) | 3 (1.1) | 1 (0.3) | 281 (99) | 3 (1.1) | 1 (0.4) |
| C. glabrata | |||||||||||||||
| Blood | 0 | 22 (96) | 1 (4) | 22 (96) | 0 | 1(4) | 22 (96) | 1(4) | 0 | 23 (100) | 0 | 0 | 5 (22) | 18 (78) | 0 |
| Peritoneal | 0 | 27 (93) | 2 (7) | 29 (100) | 0 | 0 | 29 (100) | 0 | 0 | 28 (97) | 1 (3) | 0 | 7 (24) | 21 (72) | 1 (3) |
| Other | 0 | 12 (92) | 1 (8) | 12 (92) | 0 | 1(8) | 13 (100) | 0 | 0 | 13 (100) | 0 | 0 | 5 (38) | 7 (54) | 1 (8) |
| All (65) | 0 | 61 (93.8) | 4 (6.2) | 63 (96.9) | – | 2(3.1) | 64 (98.5) | 1 (1.5) | 0 | 64 (98.5) | 1 (1.5) | 0 | 17 (26) | 46 (70.8) | 2 (3.1) |
| C. parapsilosis | |||||||||||||||
| Blood | 13 (81) | 1 (6) | 2(13) | 16 (100) | 0 | 0 | 16 (100) | 0 | 0 | 16 (100) | 0 | 0 | 14 (100) | 0 | 0 |
| Peritoneal | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | 1 (100) | 0 | 0 |
| Other | 1 (50) | 0 | 1 (50) | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 |
| All (20) | 16 (80) | 1 (5) | 3 (15) | 20 (100) | 0 | 0 | 20 (100) | 0 | 0 | 20 (100) | 0 | 0 | 17 (85) | 1 (5) | 2 (10) |
| C. tropicalis | |||||||||||||||
| Blood | 3 (100) | 0 | 0 | 3 (100) | 0 | 0 | 3 (100) | 0 | 0 | 3 (100) | 0 | 0 | 3 (100) | 0 | 0 |
| Peritoneal | 9 (82) | 0 | 2 (18) | 11 (100) | 0 | 0 | 11 (100) | 0 | 0 | 11 (100) | 0 | 0 | 11 (100) | 0 | 0 |
| Other | 6 (100) | 0 | 0 | 6 (100) | 0 | 0 | 6 (100) | 0 | 0 | 6 (100) | 0 | 0 | 5 (83) | 1 (17) | 0 |
| All (20) | 18 (90) | 0 | 2 (10) | 20 (100) | 0 | 0 | 20 (100) | 0 | 0 | 20 (100) | 0 | 0 | 19 (95) | 1 (5) | 0 |
Susceptibility categories were determined according to the CLSI Clinical Break Points (CBP) as susceptible (S), intermediate (I), and resistant (R) or the E-coff values (ECV) as wild type (WT) and non-wild type (non-WT) when CBPs are not available (Clinical and Laboratory Standards Institute [CLSI], 2012). ∗Because of the low numbers of strains within other species than the four detailed in the table, susceptibility data are not detailed.